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Abstract
Aims Recent studies have shown that serum microRNA (miR) abundance is informative for the diagnosis or prognosis
of heart failure. However, the dynamics and kinetics of miRs in acute heart failure are largely unknown. Serial measure-
ment and analysis of serum miRs changes in individuals along their therapeutic course could reduce inter-individual
variation and should detect potentially important serum miRs related to disease mechanisms. Based on this concept,
we proﬁled serum miR signatures of blood samples that were obtained sequentially on the day of admission and on
hospital Day 7.
Methods and results This prospective, observational study included 42 consecutive acute heart failure patients (74 
1 years old, 24 male). From admission to Day 7, most of the patients showed clinical improvement. In such a cohort, we
detected several ﬂuctuations of serum miRs by two distinct screening methods (quantitative PCR and high-throughput
sequencing). One of these ﬂuctuating serum miRs, miR-122-5p, decreased signiﬁcantly from Day 1 to Day 7 [median arbi-
trary unit (1st:3rd quantile value); 4.62 [2.39:12.3] to 3.07 [1.67:5.39], P = 0.007]. This ﬂuctuation was signiﬁcantly corre-
lated with changes in serum liver function markers (estimated coefﬁcient and 95% conﬁdence interval; vs change in
aspartate aminotransferase 1.69, 0.890–2.484, P < 0.001 and r = 0.560, vs change in alanine aminotransferase 1.09,
0.406–1.771, P = 0.007 and r = 0.428).
Conclusions The serum miR signature of patients with acute heart failure might indicate the severity of the disease or
patients’ response to therapeutic intervention. Notably, serum miR-122-5p levels reﬂect liver damage in this condition.
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Introduction
Heart failure is increasing in incidence and is having a huge
impact on medicine and medical economics. Heart failure
includes many pathophysiological conditions and its severity
has wide variations from sudden death to a stable state that
is observable for years. To manage this complex syndrome
effectively, appropriate deﬁnition, classiﬁcation, and stan-
dardization of treatments are essential. To accomplish this
mission, many researchers have already developed and
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tested numerous biomarkers. Among them, serum protein
biomarkers such as brain natriuretic peptide or cardiac tro-
ponins have excellent clinical value and are used fre-
quently.1,2 However, these generalized heart failure
biomarkers cannot provide speciﬁc information about hemo-
dynamics or organ damage caused by the disease. To meet
these demands, the development of new speciﬁc biomarkers
is urgently required.
Numerous reports have showed that serum microRNAs
(miRs) could be speciﬁc biomarkers for various diseases. miRs
circulate in the blood stream enclosed in small vesicles called
exosomes.3,4 Thus, these circulating miRs are stable in the
blood and there are several established methods for their
extraction and measurement. There are already many
reports, including ours, that show circulating miRs are good
biomarkers for cardiovascular diseases.5–16
To explore newbiomarkers for heart failure, we need to take
account of the deﬁnition of biomarkers, which are diagnostic,
prognosis predictive and responsiveness to disease conditions.
In the ﬁeld of heart failure, many candidatemiRs have been re-
ported from the viewpoint of diagnostic properties.7–12 Some
miRs are reported to have prognostic value.13–16 However,
not many reports have elucidated the biological meanings of
serummiRs in patients with heart failure. For example, it is un-
known whether increased serum miRs in patients compared
with healthy controls are pathological or physiological. This is
partly because many of these diagnostic or prognosis-related
miRs are obtained from case–control studies. Case–control
study designs can effectively pick-up disease-related markers.
However, inter-individual comparison cannot always give in-
formation on causal pathophysiological relationships. More-
over, inter-individual differences, especially between
diseased patients and healthy controls, often provide uncon-
trollable large biases that mask subtle changes in indicators
in response to the disease state transition.
Heart failure is a common but unique disorder, in which we
can observe a dynamic transition of condition from acute
decompensation to its resolution in a relatively a short time
period. These characteristics enable us to identify disease-
dependent transitions of biomarkers. Characterizing the
changes in miRs-signature in response to the severity of heart
failure might highlight important disease-related markers and
elucidate pathophysiological meanings of serum circulating
miRs in heart failure.
Based on such concepts, we designed and conducted this
study. Blood samples were collected sequentially from
patients with acute cardiac decompensation. The ﬁrst
samples were obtained at the peak of decompensation
and the second samples were collected from the same indi-
viduals after therapeutic intervention. In such a study de-
sign, we observed that several serum miRs changed in
response to heart failure therapy. In particular, serum miR-
122-5p changed in parallel with liver injury markers in this
short time period.
Methods
Patients inclusion, blood samples, and clinical data
collection
Blood samples and clinical data were collected from 42 con-
secutive patients who required admission to treat new-onset
heart failure or acute aggravation of chronic heart failure.
Diagnosis of heart failure was made by more than two cardi-
ologists, based on physical examination, electrocardiography,
chest radiography, echocardiography, and laboratory tests.
Echocardiography was performed on the day of admission.
Blood samples were collected within 6 h after admission in
serum separator tubes (Neotube, Nipro, Osaka, Japan) and
incubated at room temperature at least 30 min. Then, the
samples were centrifuged at 3500 rpm for 10 min and serum
was dispensed to 2 mL tubes as aliquots and stored at 80°C
until analysis. Clinical data were obtained from direct inter-
view or chart review. The study protocol was approved by
the clinical ethical board of Hyogo Prefectural Amagasaki
Hospital and Kyoto University Hospital. Written informed
consent was obtained from all participants.
Screening experiments
Two sets of pooled serum samples (Day 1 and Day 7)
obtained from the ﬁrst 10 patients were screened for ﬂuctu-
ating miRs by two distinct methods; quantitative PCR (qPCR)
panel and high-throughput sequencing (HTS). These methods
were performed in parallel and the intersection of ﬂuctuating
miRs in these two assays was validated in individual samples
using qPCR.
MicroRNA proﬁling by high-throughput sequencing
Exosomes were isolated using ExoQuick polymer precipitation
methods (System Biosciences, Mountain View, CA, USA) from
pooled serum. Exosome RNA was puriﬁed from isolated
exosomes using a SeraMir RNA kit (System Biosciences). RNA
NGS libraries were constructed using modiﬁed Illumina
adapter methods with a TailorMix miRNA Sample Preparation
Kit (SeqMatic, Inc. Fremont, CA, USA) and indexed with
separate bar codes for multiplex sequencing on either a HiSeq
2500 instruments using a 1 × 50 bp single-end run setting. All
procedures were performed in accordance with the manufac-
turer’s instructions. The output sequences were ﬁltered by se-
quence quality, and trimmed of adapter sequences. The
remaining sequences were aligned to the human genome
build 37. Read counts for each miR were calculated based
on genomic feature format ﬁle obtained from the miRbase
website (http://www.mirbase.org/ftp.shtml). Inter-sample
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normalization was performed using R17 and the DESeq pack-
age.18 Brieﬂy, as a normalization factor, the size factor was ob-
tained as a median of the geometric mean of each miRNA
read count. The calibrated read counts were calculated by








MicroRNA proﬁling by quantitative PCR panel
Exosomes were isolated from 500 μL of pooled serum using a
miRCURY Exosome Isolation Kit (Exiqon, Vedbaek, Denmark)
and a miReasy kit (QIAGEN, Valencia, CA, USA) in accordance
with the manufacturer’s instructions with a ﬁnal volume of
50 μL. Twenty microliter of isolated RNA was used for cDNA
synthesis using a Universal cDNA synthesis kit II (Exiqon).
The synthesized cDNA was diluted 50 times and applied for
qPCR panel analysis (Human miRNome miR PCR panel I+II).
miRs with Cq values more than 40 were regarded as invalid.
The inter-plate variances were normalized by inter-plate
calibrators, which were loaded onto each plate (raw CQ
values—mean IPC CQ values). After inter-plate calibration,
inter-sample normalization was performed by subtracting
prespeciﬁed miR Cq values (miR-425-5p, miR-423-5p, miR-
103-3p, miR-191-5p, and miR-93-5p). In the previous report,
miR-423-5p was shown to be a heart-failure-related miRNA.
We normalized miR 423-5p using four inter-sample calibra-
tors, excluding miR-423-5p. However, we did not see signiﬁ-
cant expression changes between the Day 1 and Day 7
samples (log twofold change = 0.27).













Serum samples were thawed and centrifuged at 13 000 g for
10 min and 300 μL of supernatant was collected. Exosomes
were isolated from serum using a miRCURY Exosome
Isolation Kit (Exiqon) in accordance with the manufacturer’s
instructions. Brieﬂy, 120 μL of precipitation buffer was added
to serum, which was incubated on ice for 60 min to precipitate
exosomes and then centrifuged at 1 500 g for 30 min at 4°C.
The pellet was subsequently re-suspended in 160 μL of resus-
pension buffer. Isolated exosomes were lysed in 750 μL of
QIAzol (QIAGEN) detergent that includes 1.5 pmole of Sp6
RNA (Exiqon) and 1 μg MS2 RNA (Roche, Basel, Switzerland).
RNA was extracted from this lysate in accordance with the
manufacturer’s instructions include in the miR easy kit
(QIAGEN). Finally, RNA was eluted in 40 μL of nuclease free
water and 2 μL of the solution was used for cDNA synthesis.
Reverse transcription was performed in 10 μL volume using
the Universal cDNA synthesis Kit (Exiqon). One-fortieth of
the obtained cDNA was used for individual qPCR assays using
a miRCURY micro-RNA assay (Exiqon) and Light cycler LC96
system (Roche). Sp6 RNA level was concomitantly measured
and used as an internal control. In this article, the serum con-
centrations of miR-122-5p in individual assays are expressed
as an estimated concentration that was determined using
the spike-in SP6 concentration. The coefﬁcient of variation
of CqmiR122 was 3.8% in our assay protocol.
Normal human organ expression level
RNAs extracted from normal human organs were purchased
from Clontech (Mountain View, CA, USA). Ten nanogram of
total RNA was used for reverse transcription reactions as de-
scribed earlier and one-eightieth of synthesized cDNA was
used for qPCR reactions.
Data representation and statistical analysis
Normally distributed continuous variables were summarized
as mean  standard deviation and tested using t-test. Contin-
uous variables with skewed distribution were summarized as
median and ﬁrst and third quintiles, and tested using
Wilcoxon rank sum test. All comparisons between Day 1
and Day 7 data were tested as paired samples. Correlations
were assessed using Pearson correlation coefﬁcients and
summarized as estimated coefﬁcients and its 95% conﬁdence
interval. Multivariate analysis was performed using multiple
linear regression model to test independency of explanatory
variables, which showed signiﬁcant correlations in single
variable analysis. All statistical tests were performed using R
software version 3.1.2.
Results
Patient characteristics and the therapeutic
responses
In this study, 42 acute heart failure patients were enrolled.
Tables 1 and 2 show the baseline characteristics and echocar-
diographic variables of the study population. The mean age
was over 75 years old, and average ejection fraction was
around 45%. These data are roughly consistent with a
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previously reported large-scale registry series of acute heart
failure.19,20
Changes in clinical variables during the therapeutic course
are shown in Tables 3 and 4. Blood pressure, heart rate, body
weight, and oxygen demand were decreased in response to
therapeutic intervention. The resolution of laboratory tests
was also observed. Abnormalities in liver function tests were
improved, and serum natriuretic peptide and troponin levels
decreased. However, the indices of renal function worsened,
which may be the result of successful aggressive volume
reduction.
Screening and validation for ﬂuctuating microRNA
and validation
To obtain a precise and reproducible result, we performed
two distinct screening methods, qPCR panel and HTS.
Fluctuating miRs levels detected in both methods were con-
sidered as candidates for further evaluation. Sera from the
ﬁrst 10 patients in our study population were pooled and an-
alyzed by qPCR panel and HTS. A summary of the results of
screening experiments with the two assay systems is shown
in Figure 1. HTS-based and qPCR-based methods detected
187 and 167 miRs at both time points. Among these miRs,
125 were detected in both methods and at both time
points. The relative changes detected in these systems
showed signiﬁcant correlations (r > 0.6, Supporting Informa-
tion Figure S1). We plotted these detected miRs in Figure 2,
and highlighted miRs with names that showed consistently
increases or decreases by more than twofold in both
methods. Some of these differently expressing miRs, such
as miR-16-5p, miR-92-3p, miR-486-5p, miR-25-3p, and miR-
101-3p, are the members of miRs that are known to exist
abundantly in red blood cells21 and their copy numbers in
serum are also known to be increased by hemolysis. Al-
though the pathophysiological signiﬁcance of hemolysis in
heart failure is still unclear, we excluded these miRs from
the validation experiment in this study. After excluding these
hemolysis-related miRs, miR-122-5p was the most abundant
and signiﬁcantly changed miR. To validate this ﬂuctuation,
we measured miR-122-5p levels in each sample by qPCR.
As shown in Figure 3 and Figure S2, miR-122-5p levels were
signiﬁcantly decreased from Day 1 to Day 7.
Liver function test abnormalities and miR-122-5p
To clarify the physiological signiﬁcance of this change, we
explored the origin of miR-122-5p in the human body. We
measured expression levels of miR-122-5p in normal human
organs. As shown in Figure 4, miR-122-5p was speciﬁcally
and abundantly expressed in the liver. This result was consis-
tent with previous reports.22 Thus, we hypothesized that
serum miR-122-5p might reﬂect liver damage and assessed
correlations between miR-122-5p level and standard liver
damage markers. As shown in Figure 5, miR-122-5p expres-
sion levels in serum showed good correlations with serum
aspartate aminotransferase (AST) and alanine aminotransfer-
ase (ALT) levels.
In our cohort, patients showed an increased level of liver
damage markers on admission, and these abnormalities im-
proved after therapeutic intervention. We also assessed
whether this resolution could be detected using serum miR-
122-5p levels. Figure 6 showed the correlation between
changes in serum liver function markers and serum miR-
122-5p levels. Serum miR-122-5p levels also decreased
consistently with serum liver injury markers. Correlations
between miR-122-5p changes and other indices are shown
in Tables 5 and 6. Pretreatment with diuretics before admis-
sion and larger decrease in body weight achieved by therapy
Table 1 Baseline characteristics
Age (years) 75.7  11.4
BMI 22.0  4.2
Gender, male (%) 45 (19)
Concomitant disorders (%)
Ischemic heart disease 48 (20)
Atrial ﬁbrillation 45 (19)
With pacemaker 21 (9)
Diabetes 48 (20)
Medication on admission (%)
RAS inhibitor 40 (17)
Aldosterone blocker 31 (13)
Beta blocker 45 (19)
Loop diuretic 74 (31)
Thiazide diuretic 7 (3)
Antiplatelet 48 (20)
Anticoagulant 38 (16)
Calcium channel blocker 43 (18)




Natriuretic peptide 33 (14)
BMI, Body mass index; RAS, Renin angiotensin system.
Data is expressed as mean  standard deviation or percentage
(count).
Table 2 Echocardiographic variables
LVDd (mm) 45.9 [40.5:51.7]
LVDs (mm) 33.1 [28.2:43.7]
IVSd (mm) 11.5  2.6
PWTd (mm) 12.6  2.5
LADs (mm) 42.5 [39.0:48.7]
Teichholz-EF (%) 44.6  18.8
Modiﬁed Simpson-EF (%) 46.5  18.6
EF, ejection fraction; IVSd, interventricular septumthickness enddia-
stolic; LVDd, left ventricular internaldiameterenddiastolic; LVDs, left
ventricular internal diameter end systolic; LADs, left atrial internal
diameter end systolic; PWTd, posterior wall thickness end diastolic.
Data is expressed as mean  standard deviation or median (1st:3rd
quantile value).
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showed positive relationships with miR-122-5p levels. Even
after correction for these factors, the ﬂuctuation in liver in-
jury markers was the strongest determinant of miR-122-5p
changes (Table 7).
Discussion
In this study, we successfully observed dynamic changes in
serum miR-122-5p abundance through therapeutic courses
for acute heart failure using two distinct screening methods,
qPCR panel and HTS. Quantiﬁcation of miR-122-5p levels in
individual samples revealed a substantial correlation
Table 4 Correlations between clinical characteristics or changes in




Age (years) 0.024 [0.028:0.075] 0.357
BMI (kg/cm2) 0.231 [2.883:3.345] 0.882







Δ Heart rate 0.752 [-1.979:3.483] 0.581
Δ Systolic blood pressure 0.001 [0.023:0.020] 0.916
Δ Diastolic blood pressure 0.015 [0.043:0.013] 0.291
Δ Body weight 10.618 [0.384:20.853] 0.042
Estimated Pearson’s correlation coefﬁcients and its 95% conﬁ-
dence interval (CI) are shown.
Table 3 Changes of clinical parameters
Day 1 Day 7 P-value
Heart rate (/min) 82.5 [68.2:103.2] 71.5 [60.0:81.0] <0.001
Systolic blood pressure (mmHg) 139.2  31.6 122.3  18.2 <0.001
Diastolic blood pressure (mmHg) 77.3  23.3 69.1  12.4 0.013
Body weight (kg) 53.6 [47.0:63.6] 50.0 [41.4:60.9] <0.001
Oxygen requirement 40% (17) 17% (7) 0.030
White blood cell count (108/mL) 61.3  17.8 57.1  15.2 0.136
Red blood cell count (108/mL) 349  70.9 367  79.9 0.006
Hemoglobin (g/dL) 10.6  2.1 11.1  2.3 0.017
Platelet count (1010/mL) 19.6  6.7 22.0  6.6 <0.001
Albumin (g/dL) 3.4  0.5 3.3  0.6 0.305
AST (IU/L) 23.0 [18.2: 31.0] 18.0 [15.0:21.0] <0.001
ALT (IU/L) 17.0 [11.2:26.0] 12.5 [9.2:19.5] <0.001
ALP (IU/L) 241.5 [197:344] 226.0 [172:271] <0.001
Total bilirubin (mg/dL) 0.60 [0.50:0.98] 0.50 [0.40:0.80] 0.008
Blood urea nitrogen (mg/dL) 23.4 [16.8:34.2] 34.7 [25.1:49.0] <0.001
eGFR (mL/min/1.73 cm2) 44.2  26.0 39.1  24.8 0.001
Sodium (mEq/L) 139.9  3.9 140.8  5.5 0.281
Potassium (mEq/L) 3.95  0.57 4.01  0.44 0.518
CPK (IU/L) 91.5 [61.5:210.5] 45.5 [36.2:65.8] <0.001
CRP (mg/dL) 0.60 [0.18:1.31] 0.51 [0.23:1.53] 0.746
BNP (pg/mL) 586 [385:872] 261 [189:535] <0.001
Troponin I (ng/mL) 0.050 [0.034:0.162] 0.027 [0.014:0.066] 0.003
ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, Aspartate aminotransferase; BNP, Brain natriuretic peptide; CPK, Creatine
phosphokinase; CRP, C-reactive protein; eGFR, Estimated glomerular ﬁltration ratio.
Data is expressed as percentage (count), mean  standard deviation or median (1st:3rd quintile value).
Figure 1 Screening schema and its consistency. (A) The number of
microRNAs (miRs) detected by quantitative PCR (qPCR) or high-through-
put sequencing (HTS) in both Day 1 and Day 7 samples shown in a Venn
diagram. (B) Consistency of screening result about each miRs. ‘Decreased’
indicates the number of miRs whose abundance at Day 7 was decreased
from Day 1. ‘Increased’ indicates the abundance at Day 7 was increased
from Day 1.
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between the changes in miR-122-5p and serum liver injury
markers. This is the ﬁrst report that shows a serum miR
pattern reﬂects organ damage caused by acute heart failure
and these changes occurred within a clinically relevant
period. These properties support the application of miRs as
point-of-care biomarkers.
At present, the mechanism of the serum miR-122-5p
increase remains to be elucidated. However, miR-122-5p is
speciﬁcally expressed in the liver in human22 and data from
patients with hepatitis and in vitro data suggest that miR-
122-5p released from the liver is based on the destruction
of hepatocytes.23 Therefore, it is reasonable to suppose that
the ﬂuctuation in serum miR-122-5p levels could reﬂect liver
damage caused by acute heart failure. This is consistent with
the observation that heart failure patients are prone to liver
damage based on hemodynamic abnormalities. In line with
our results, Nikolaou et al. showed serum liver function
markers were elevated on admission for acute heart failure,
and these abnormalities improved in parallel with clinical res-
olution.24 They also showed signiﬁcant relationships between
baseline liver function tests and prognosis. Indeed, patients
who needed therapy with intravenous inotropic agent did
not show tendencies for a decrease in miR-122-5p from Day
1 to Day 7, which may indicate the sustained liver damage
still occurs in such severe cases.
Figure 2 Changes in the serum microRNA signature. Screening result from high-throughput sequencing (HTS) (A) and quantitative PCR (qPCR) (B).
Horizontal axis indicates relative abundance in each method. Vertical axis indicates relative change as log 2-fold change.
Figure 3 Fluctuation of serum microRNA (miR)-122-5p level in individual
samples. Two dots connected with a line indicated the samples from one
patient. Signiﬁcance was tested using a paired Wilcoxon rank sum test.
Figure 4 MicroRNA (miR)-122-5p expression in normal human organs.
Relative expression levels are expressed as relative values to miR-122-
5p in the heart.
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Some reports have examined the relationship between
miR-122-5p and heart failure. Corsten et al. showed that
serum miR-122-5p was increased in patients with acute heart
failure.25 On the contrary, Fukushima et al. reported no
relationship between miR-122-5p and New York Heart
Association (NYHA) functional status in patients with chronic,
stable heart failure.26 This discrepancy might partly be
explained by the ﬂuctuation that was observed in our study.
That is, heart failure patients showed increased miR-122-5p
in serum in the acute phase with liver injury, but they did
not show any elevation of miR-122-5p in serum during the
stable phase. This ﬁnding was also consistent with the obser-
vation that patients with cirrhosis but without ongoing liver
damage do not show elevated serum miR-122-5p level.23
Figure 5 Correlation between serum microRNA (miR)-122-5p and AST or ALT activities. Aspartate aminotransferase (AST) and alanine aminotransfer-
ase (ALT) activity are expressed after log 2 transformation. miR-122-5p was expressed in arbitrary units (AUs). The red line indicates the estimated
regression line. Dotted lines show 95% conﬁdence intervals of the estimated regression line.
Figure 6 Correlation between changes of serum microRNA (miR)-122-5p and changes of aspartate aminotransferase (AST) or alanine aminotransferase
(ALT) activities. Relative changes in miR-122-5p, AST and ALT activity are shown after log 2 transformation. The red line indicates the estimated regres-
sion line. Dotted lines show the 95% conﬁdence interval of the estimated regression.
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On the other hand, we did not detect a signiﬁcant ﬂuctua-
tion of known heart failure-related miRs, such as miR-423-5p,
miR-22, miR-320a. miR-92b, miR-208, and miR-499, in this
study. This result was consistent with the previous report by
Seronde et al.27 They measured several heart-failure-speciﬁc
serum miRs (miR-1, miR-21, miR-126, and miR-423-5p) on ad-
mission and the ﬁfth admission day and did not see any sig-
niﬁcant ﬂuctuations. It seems that these markers were
relatively stable in patients with heart failure irrespective its
severity or speciﬁc characteristics.
The physiological signiﬁcance of the presence of miRs in
the serum of heart failure patients has been largely
unclear. Our result advocates a concept that some of the
ﬂuctuating serum miRs in patients with acute heart failure
could reﬂect the organ damage caused by hemodynamic
abnormality. Additionally, short-term resolution of organ
damage could also be observed as a change in serum miRs.
Based on these ﬁndings, measurement of organ-speciﬁc
miRs might afford effective ways to monitor organ damage,
which is caused by acute heart failure or other etiologies.
Moreover, measurement of serum miRs on other settings
or speciﬁc subtypes of heart failure, could identify a variety
of miRs that relate to speciﬁc conditions or heart failure
subtypes.
Circulating miRNAs in the blood now offer a new form of
biomarker for disease diagnosis. Recent studies have pro-
posed the use exosomal miRNAs as diagnostic markers in
human diseases,28 because the quantity of miRNAs in
exosomes exhibited greater differences between healthy
individuals and cancer patients than observed in sera.29 It
was also shown that more reads of miRNAs are detected
in exosomal samples compared with those detected in
serum or plasma.30 Therefore, we utilized exosome-derived
miRNA for the analysis. Traditional isolation of exosomes
from body ﬂuids is based on ultracentrifugation in combi-
nation with sucrose density gradients or sucrose cushions
to ﬂoat the relatively low-density exosomes away from
other vesicles and particles. These protocols can take up
to 30 h and are not suitable for assaying many samples.
Recently, several polymers have been developed for the
isolation of exosomes. By tying up water molecules, the
polymer forces less-soluble components, such as vesicles,
out of solution, which allows them to be collected easily
using a short, low-speed centrifugation step. Thus, many
Table 5 Relationships between clinical characteristics and serum microRNA (miR)-122-5p change
Explanatory variable (number of yes) No Yes P-value
Male (23) 1.51 [1.14:3.36] 1.52 [0.74:3.29] 0.783
Ischemic heart disease (20) 2.14 [0.86:3.45] 1.38 [0.70:2.35] 0.225
Atrial ﬁbrillation (19) 1.52 [0.76 :3.09] 1.46 [0.77:3.56] 0.745
Diabetes (20) 1.49 [0.70:2.53] 1.92 [0.79:4.38] 0.288
Viral hepatitis (2) 1.49 [0.75:3.27] 3.35 [2.98:3.71] 0.281
RAS inhibitor (17) 1.52 [0.80:2.63] 1.46 [0.73:3.94] 0.960
Aldosterone blocker (13) 1.52 [0.80:2.63] 1.46 [0.63:4.07] 0.591
Beta blocker (19) 1.47 [0.78:2.62] 1.68 [0.76:4.14] 0.671
Loop diuretics (31) 2.63 [1.36:5.98] 1.46 [0.70:2.56] 0.041
Statin (14) 1.49 [0.79:2.86] 1.52 [0.68:3.75] 0.927
Antiplatelet (20) 1.52 [0.86:2.60] 1.49 [0.71:3.98] 0.832
Anticoagulant (16) 1.49 [0.79:3.31] 1.67 [0.70:3.37] 0.828
Calcium channel blocker (18) 1.35 [0.67:3.67] 1.67 [1.31:3.04] 0.413
Oxygen requirement, Day 1 (17) 1.68 [0.79:3.18] 1.24 [0.73:3.54] 0.309
Oxygen requirement, Day 7 (7) 1.52 [0.77:2.91] 1.47 [0.88:3.81] 0.974
Inotrope use (6) 1.60 [0.79:3.64] 1.02 [0.69:1.42] 0.159
Natriuretic peptide use (15) 1.51 [0.70:2.62] 1.52 [1.14:4.01] 0.482
Nitroglycerin use (13) 1.52 [0.75:3.98] 1.47 [0.79:2.63] 0.839
RAS, Renin angiotensin system.
Data are presented as median of Day1/Day7 miR-122-5p (AU) and [1st:3rd quantile value]. Statistical signiﬁcances were tested using
Wilcoxon-rank sum tests.
Table 6 Correlations between serum laboratory measurements




Δ White blood cell count 0.023 [0.009:0.055] 0.157
Δ Red blood cell count 0.001 [0.015:0.014] 0.923
Δ Hemoglobin 0.014 [0.521:0.493] 0.955
Δ Platelet count 0.044 [0.089:0.177] 0.509
Δ Albumin 1.247 [0.168:2.662] 0.083
Δ AST 2.434 [1.284:3.583] <0.001
Δ ALT 1.570 [0.585:2.554] 0.003
Δ ALP 4.479 [1.927:7.031] 0.001
Δ Total bilirubin 0.215 [1.331:1.761] 0.780
Δ Blood urea nitrogen 0.069 [1.375:1.512] 0.924
Δ GFR 0.007 [0.055:0.069] 0.821
Δ Sodium 0.046 [0.155:0.063] 0.400
Δ Potassium 0.886 [0.070:1.842] 0.069
Δ Creatine kinase 0.958 [0.013:1.929] 0.053
Δ CRP 0.046 [0.509:0.418] 0.844
Δ BNP 0.628 [0.304:1.560] 0.180
Δ Troponin-I 0.362 [-0.273:0.998] 0.255
ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; AST, As-
partate aminotransferase; BNP, Brain natriuretic peptide; CPK, Cre-
atine phosphokinase; CRP, C-reactive protein; eGFR, Estimated
glomerular ﬁltration ratio; NT-pro BNP, N-terminal pro BNP.
Estimated Pearson’s correlation coefﬁcients and its 95% conﬁ-
dence interval (CI) are shown.
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reports on exosomes-derived RNA have already been pub-
lished by use of this method without any internal control.31–36
In conclusion, we found a dynamic miR signature transition
in a timely fashion during the therapeutic course for acute
heart failure. Among these miRs, serum miR-122-5p levels
reﬂected liver damage in this condition. These ﬁndings
warrant the importance of a larger study about the relation-
ships between serial measurement of miRs and clinical
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Figure S1. Correlation between two screening experiments.
Abundance determined by high-throughput sequencing
(HTS) is shown on the horizontal axis and abundance deter-
mined by quantitative PCR (qPCR) is shown on the vertical
axis. Only microRNAs (miRs) that were detected by both
methods are shown. Pearson’s correlation coefﬁcient be-
tween experiments is shown.
Figure S2. Distribution of serum microRNA (miR)-122-5p
abundance and change. Distribution of miR-122-5p abun-
dance at each time point is shown in Figure S2A. Changes
in miR-122-5p abundance are also shown in Figure S2B. The
number of patients is shown on the horizontal axis. Relative
abundances or relative changes are shown on the vertical
axis.
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